Mark A. Stamnes

In vivo CRISPR screening links NFKB1 to endocrine resistance in ER+ breast cancer

Resistance to endocrine therapy (ET) remains a major clinical challenge in the treatment of estrogen receptor-positive (ER+) breast cancer, underscoring the need for novel therapeutic targets. To identify genetic drivers of ET resistance, we conducted an in vivo genome-wide CRISP...